Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Collaboration and license revenue | $3,047 | $14 |
| Operating expenses: | ||
| Research and development | 64,980 | 40,699 |
| General and administrative | 11,687 | 12,936 |
| Total operating expenses | 76,667 | 53,635 |
| Loss from operations | (73,620) | (53,621) |
| Other income (expense): | ||
| Interest income | 4,864 | 5,582 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's G&A?
- 4D Molecular Therapeutics (FDMT) reported G&A of $11.69M in Q1 2026.
- How has 4D Molecular Therapeutics's G&A changed year-over-year?
- 4D Molecular Therapeutics's G&A decreased by 9.7% year-over-year, from $12.94M to $11.69M.
- What is the long-term trend for 4D Molecular Therapeutics's G&A?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's G&A has grown at a 15.0% compound annual growth rate (CAGR), from $28.01M to $49.06M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about 4D Molecular Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude